Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | BRAF |
| Variant | G596R |
| Impact List | missense |
| Protein Effect | loss of function - predicted |
| Gene Variant Descriptions | BRAF G596R lies within the protein kinase domain of the Braf protein (UniProt.org). G596R results in impaired Braf kinase activity, but leads to Craf-dependent activation of Erk in culture (PMID: 19735675, PMID: 28783719, PMID: 18697864), demonstrates similar cell proliferation and viability levels to wild-type Braf (PMID: 29533785), is not transforming in culture, and does not promote tumor formation in mouse models (PMID: 19735675), and therefore, is predicted to lead to a loss of Braf protein function. |
| Associated Drug Resistance | |
| Category Variants Paths |
BRAF mutant BRAF G596X BRAF G596R BRAF mutant BRAF inact mut BRAF G596R |
| Transcript | NM_004333.6 |
| gDNA | chr7:g.140753349C>G |
| cDNA | c.1786G>C |
| Protein | p.G596R |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| XM_005250045 | chr7:g.140753349C>G | c.1786G>C | p.G596R | RefSeq | GRCh38/hg38 |
| NM_004333.6 | chr7:g.140753349C>G | c.1786G>C | p.G596R | RefSeq | GRCh38/hg38 |
| NM_001378474.1 | chr7:g.140753349C>G | c.1786G>C | p.G596R | RefSeq | GRCh38/hg38 |
| NM_001354609.1 | chr7:g.140753349C>G | c.1786G>C | p.G596R | RefSeq | GRCh38/hg38 |
| NM_004333 | chr7:g.140753349C>G | c.1786G>C | p.G596R | RefSeq | GRCh38/hg38 |
| NM_001378468.1 | chr7:g.140753349C>G | c.1786G>C | p.G596R | RefSeq | GRCh38/hg38 |
| NM_001378467.1 | chr7:g.140753358C>G | c.1786G>C | p.G596R | RefSeq | GRCh38/hg38 |
| NM_001354609.2 | chr7:g.140753349C>G | c.1786G>C | p.G596R | RefSeq | GRCh38/hg38 |
| NM_004333.5 | chr7:g.140753349C>G | c.1786G>C | p.G596R | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF G596R | colorectal cancer | sensitive | Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, Mekinist (trametinib) reduced Erk signaling and inhibited proliferation of a colorectal cancer cell line harboring BRAF G596R in culture (PMID: 28783719). | 28783719 |
| BRAF G596R | colorectal cancer | resistant | Vemurafenib | Preclinical - Cell culture | Actionable | In a preclinical study, Zelboraf (vemurafenib) did not reduce activation of Erk and Mek in a colorectal cancer cell line harboring BRAF G596R in culture (PMID: 28783719). | 28783719 |
| BRAF G596R | colorectal cancer | sensitive | Dabrafenib + Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in decreased proliferation and increased apoptosis, and enhanced ERK inhibition compared to either agent alone in a colorectal cancer cell line harboring BRAF G596R in culture (PMID: 28947956). | 28947956 |
| BRAF G596R | colorectal cancer | predicted - sensitive | RMC-4550 | Preclinical - Cell culture | Actionable | In a preclinical study, RMC-4550 inhibited Erk phosphorylation and proliferation of colorectal cancer cells harboring BRAF G596R in culture (PMID: 30104724). | 30104724 |
| BRAF G596R | Advanced Solid Tumor | no benefit | Vemurafenib | Clinical Study - Cohort | Actionable | In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in an objective response in only 4% (1/23) of patient with advanced solid tumors harboring non-V600 BRAF mutations, 1 of the non-responding patients harbored BRAF G596R (PMID: 29320312; NCT02091141). | 29320312 |
| BRAF G596R | lung non-small cell carcinoma | no benefit | Vemurafenib | Case Reports/Case Series | Actionable | In a Phase II trial, Zelboraf (vemurafenib) treatment did not result in response in the cohort of 15 non-small cell lung cancer patients with non-V600 BRAF mutations, which included 1 patient harboring BRAF G596R, and enrollment in this cohort was discontinued (PMID: 31959346; NCT02304809). | 31959346 |
| BRAF G596R | colorectal cancer | predicted - sensitive | PLX8394 | Preclinical - Cell culture | Actionable | In a preclinical study, colorectal cancer cells harboring BRAF G596R demonstrated sensitivity to PLX8394 treatment in culture (PMID: 30559419). | 30559419 |
| BRAF G596R | colorectal cancer | sensitive | JAB-3312 | Preclinical - Cell culture | Actionable | In a preclinical study, JAB-3312 inhibited viability of a colorectal cancer cell line harboring BRAF G596R in culture (PMID: 40333694). | 40333694 |